Highlights

  • Canaccord Genuity issues a Buy rating with target price of AUD 46.50
  • Shares traded at AUD 31.960 on 16 April 2026, down 2.26% during the session
  • Q2 FY2026 revenue rises 11% to USD 1.4 billion with strong margin expansion

Shares of ResMed Inc (ASX:RMD) traded at AUD 31.960 on 16 April 2026, recording a decline of 2.262% or AUD 0.740 during the session. The stock moved within a narrow bid-offer range of AUD 31.940 to AUD 31.960, indicating stable pricing pressure rather than volatile intraday swings.

Trading volume stood at 1.12 million shares, reflecting moderate investor participation in line with typical activity for a large-cap healthcare stock. With a market capitalisation of approximately AUD 47.42 billion, ResMed remains one of the most significant healthcare technology companies listed on the ASX and NYSE.

Despite the day’s weakness, broader investor focus remains anchored on the company’s earnings trajectory, margin expansion, and structural demand for sleep apnea treatment solutions.

Canaccord Genuity Maintains Buy Rating

Investment firm Canaccord Genuity has reiterated a Buy rating on ResMed, with a target price of AUD 46.50.

The rating reflects long-term confidence in ResMed’s leadership position in the sleep and respiratory care market. Analysts continue to emphasise the company’s ability to generate recurring demand through its connected care ecosystem, device innovation, and software-enabled patient monitoring solutions.

Importantly, the Buy recommendation is based on structural industry growth drivers rather than short-term earnings fluctuations, highlighting expectations of sustained global adoption of sleep disorder therapies.

Q2 FY2026 Earnings Performance

ResMed delivered a solid financial performance for the second quarter of FY2026, with revenue increasing by 11% to USD 1.4 billion, or 9% on a constant currency basis. Growth was driven primarily by increased demand for sleep devices, masks, and accessories.

Revenue growth was geographically balanced, with the Americas region delivering an 11% increase, while Europe, Asia, and other international markets grew 6% on a constant currency basis. Residential care software also contributed modestly, growing 5%.

The company also reported strong profitability expansion. Gross margin increased by 320 basis points to 61.8%, supported by manufacturing efficiencies, logistics optimisation, and lower component costs. On a non-GAAP basis, gross margin reached 62.3%.

Operating income increased by 18%, while non-GAAP operating income rose 19%, reflecting strong operational leverage from revenue growth and margin improvement.

Earnings and Cash Flow Strength

Net income for the quarter reached USD 393 million, while diluted earnings per share stood at USD 2.68. On a non-GAAP basis, earnings per share increased to USD 2.81, up 16% year-on-year.

Operating cash flow remained strong at USD 340 million, slightly below net income due to working capital dynamics but consistent with the company’s cash-generative business model.

ResMed also continued its capital return program during the quarter, distributing USD 88 million in dividends and repurchasing approximately 704,000 shares for USD 175 million, reflecting disciplined capital management and shareholder distribution strategy.

Product Innovation and Clinical Evidence

A key feature of ResMed’s growth strategy is its continued investment in digital health and clinical innovation. During the period, the company published large-scale research in SLEEP involving more than 370,000 patients, demonstrating that increased adherence to positive airway pressure (PAP) therapy is associated with reduced healthcare utilisation.

The company also received FDA clearance for Smart Comfort, an AI-enabled digital medical device designed to personalise CPAP comfort settings and improve patient adherence. This development highlights the increasing integration of artificial intelligence into medical device functionality.

These innovations reinforce ResMed’s positioning as not only a device manufacturer but also a digital health solutions provider.

Connected Care Ecosystem and Market Positioning

ResMed’s strategy is increasingly centred on its connected care ecosystem, which integrates hardware, software, and cloud-based patient monitoring tools. This ecosystem allows healthcare providers to track patient compliance, optimise treatment outcomes, and improve long-term therapy adherence.

The company’s leadership in sleep apnea treatment devices, particularly continuous positive airway pressure (CPAP) systems, provides a strong recurring revenue base driven by replacement cycles, consumables, and software subscriptions.

This model enhances revenue predictability while also strengthening patient engagement across global healthcare systems.

Dividend Policy and Capital Allocation

ResMed maintained its quarterly dividend program, declaring a cash dividend of USD 0.60 per share. The dividend reflects the company’s ongoing commitment to returning capital to shareholders while maintaining investment in innovation and expansion.

The dividend structure is supported by consistent cash flow generation and a strong balance sheet, allowing flexibility for both reinvestment and shareholder returns.

Market Reaction and Investor Sentiment

Despite strong earnings growth and operational improvements, ResMed shares experienced a decline on 16 April 2026. The move reflects short-term market volatility rather than deterioration in fundamentals.

Investor sentiment continues to be influenced by macroeconomic factors, currency fluctuations, and broader healthcare sector rotations. However, the underlying earnings trajectory and innovation pipeline remain central to long-term valuation considerations.

The divergence between earnings strength and share price movement highlights the complexity of near-term market behaviour in large-cap healthcare equities.

Industry Outlook and Structural Growth Drivers

The global sleep apnea market continues to expand, driven by increasing diagnosis rates, ageing populations, and rising awareness of sleep-related disorders. ResMed remains a key beneficiary of these structural trends due to its established market leadership and integrated product ecosystem.

The shift toward digital healthcare solutions and remote patient monitoring further strengthens the company’s competitive positioning. Healthcare systems globally are increasingly adopting cloud-based monitoring tools, which align closely with ResMed’s technology offerings.

Conclusion

ResMed Inc’s share performance on 16 April 2026 reflects short-term market softness despite strong underlying financial results and positive structural growth drivers. The Buy rating from Canaccord Genuity, with a target price of AUD 46.50, underscores long-term confidence in the company’s leadership within the global sleep and respiratory care market. With double-digit revenue growth, expanding margins, strong cash flow generation, and continued innovation in digital health, ResMed maintains a solid operational foundation. While share price movements remain influenced by broader market dynamics, the company’s long-term growth narrative continues to be supported by sustained demand for its connected healthcare solutions.